News & AnalysisKorro Bio scores $116m Series BKorro Bio, Inc., a RNA editing company, has closed $116 million in Series B financing.ByIris Dorbian5 January 2022•1 min readJavaScript is required to read this article. Please enable it in your browser and reload the page.DealsHealthcareBriefs